A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and
Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in
Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell
Transplant is Not Planned as Initial Therapy